背景介绍： 当2025年的日历翻至末页，生物医药产业正站在一个特殊的历史节点——这既是"十四五"的收官沉淀之年，更是"十五五"宏伟蓝图的启航之时。这一年，技 术狂飙与商业理性的碰撞、全球化布局与本土化深耕的平衡、"创新驱动"向"价值驱动"的范式转型，共同勾勒出2025年的行业主线。2026年，产业如何跨越 技术周期与资本周期的双重考验，在"健康中国"战略与全球创新格局双轨并行中，探寻可持续增长路径？思享启发思想，"生物医药大健康2026思享汇：双 轨并行・破局生长"重磅上线，与核心实践者、机构与权威专家一起同行，连接生物医药大健康领域内最强思想电波！ 诺诚健华作为国内领先的综合创新生物药企，2025年是其成立十周年的里程碑之年，斩获了丰硕成果：通过与Zenas达20亿+美元重磅合作刷新行业对外授权 纪录，叠加商业化推进提前两年实现盈亏平衡；两款创新药成功上市、核心产品奥布替尼新增适应症获批并纳入医保，创新成果加速落地惠及患者；多款前 沿药物研发取得突破，在血液瘤、自免领域构建核心优势，实体瘤布局持续强化。 站在十周年新起点，诺诚健华锚定"中国原创"与"全球视野"开启下一个黄金十年，诺诚健华联合创始人、董事长兼 ...

站在"十五五"新程待启的关键时点，如何看待2026年的经济形势？2026年经济工作怎么干？新京报贝壳财经推出《看2026：十五五·启新程》专题报道，汇 聚监管部门、知名学者和领军企业家，解读政策脉络，洞察趋势变化。 对于企业而言，针对中央经济工作会议提出的持续扩大内需等议题会有哪些举措？2026年有哪些战略发展目标？新京报贝壳财经记者就此采访了诺诚健华联 合创始人、董事长兼CEO崔霁松。 the pro ppul the first 0 526 17 182 n rplayer of t A Leading to Company of September 1 a major (Carolina and Children) read the may esting 1235 t 199 Hou and the state the STERNET 301 2 and of the starter Street Pro and and STORE WARRETT t and and t t 9:11:5 01:43:45 诺诚健华联合创始人、董事长兼CEO崔霁松。受访者供图 新京报贝壳财经：中央经济工作会议提出持续扩 ...

Core Viewpoint - The Changping District has achieved a GDP growth of 7.1% in the first three quarters, surpassing national and city averages, driven by robust industrial output and strategic initiatives in modern industrial system construction [1][3]. Industrial Development - The district's industrial output value reached 118.68 billion yuan, with a year-on-year growth of 13.4%, indicating a significant acceleration in industrial performance [1]. - Key industries such as advanced manufacturing, energy, and healthcare have shown strong growth, with advanced manufacturing achieving an output of 107.39 billion yuan (up 14.3%), advanced energy at 53.58 billion yuan (up 18%), and healthcare at 30.33 billion yuan (up 1.9%) [3][6]. - Notable innovations in the healthcare sector include the clinical application of innovative drugs and advancements in AI-assisted medical technologies [4][6]. Future Industry Layout - Changping is proactively positioning itself in future industries like synthetic biology, brain science, robotics, and 6G, with a focus on creating new economic growth points [8][13]. - The synthetic biology sector has established 131 related enterprises, forming a comprehensive industrial ecosystem [9]. - The district has initiated the first industrial cluster for brain science and brain-machine interfaces, enhancing technological innovation and application [9][11]. Innovation and Collaboration - The district emphasizes collaboration between industry and academia, fostering innovation through partnerships with local universities [17]. - The establishment of various innovation parks and research centers is aimed at accelerating technology transfer and commercialization [16][17]. Urban Integration and Quality of Life - Changping is committed to integrating industrial development with urban functionality and public welfare, enhancing living conditions for residents and attracting talent [21][22]. - Initiatives include the construction of affordable housing and the development of educational and healthcare facilities to support the workforce [24][25]. - The district has improved transportation infrastructure, significantly reducing commute times and enhancing accessibility for residents and workers [25]. Economic Performance - The district's per capita disposable income increased by 5.6% in the first three quarters, reflecting the positive impact of industrial growth and urban development on residents' livelihoods [25].

Core Viewpoint - The event "Innovation Source, Health Navigation" highlights Beijing's strategic focus on the pharmaceutical and health sectors, showcasing the city's efforts to drive high-quality economic development through innovation and clinical needs [1][3][19]. Group 1: Event Overview - The event was organized by the Beijing Municipal Cyberspace Administration and featured a visit to various innovative pharmaceutical companies and research centers [1][2]. - The media delegation explored the complete path of innovative drugs from target discovery to clinical approval, emphasizing the importance of clinical needs and policy support in driving pharmaceutical innovation [2][3]. Group 2: Industry Development - The Zhongguancun Life Science Park has become a hub for innovation in China's life sciences, housing over 1,000 innovative pharmaceutical companies and several national-level research institutions [3][4]. - The park includes significant medical facilities with over 3,000 beds, supporting clinical research and the development of innovative drugs and medical devices [3]. Group 3: Company Highlights - Wantaibio invests over 1 billion yuan annually in R&D, with over 30% of its workforce dedicated to research, resulting in hundreds of innovative products, including six global firsts [12]. - Huahui Anjian focuses on developing competitive innovative drugs in virology and oncology, with several drugs in different clinical development stages, including a breakthrough therapy for hepatitis B [14]. - Nuo Cheng Jian Hua has over ten innovative drugs in clinical stages, with significant trials ongoing in China and globally, including a BTK inhibitor and a humanized monoclonal antibody [16][18]. Group 4: Innovation Ecosystem - The event emphasized the importance of a supportive research policy and industrial ecosystem in Beijing, which provides fertile ground for the growth of innovative pharmaceutical companies [19]. - The ongoing monthly thematic visits aim to promote the achievements of high-quality economic development in Beijing, focusing on key sectors such as advanced manufacturing and biomedicine [19].